Clinical Trial: An Exploratory Clinical Study Evaluating the Efficacy and Safety of Tunlametinib Combined With Fruquintinib in the Third-line Treatment of Advanced Colorectal Cancer Patients With RAS Mutations.

U.S., May 23 -- ClinicalTrials.gov registry received information related to the study (NCT06985316) titled 'An Exploratory Clinical Study Evaluating the Efficacy and Safety of Tunlametinib Combined With Fruquintinib in the Third-line Treatment of Advanced Colorectal Cancer Patients With RAS Mutations.' on May 14.

Brief Summary: This study is a prospective, open-label, single-arm clinical study aimed at evaluating the efficacy and safety of Tunlametinib combined with Fruquintinib in the third-line treatment of advanced colorectal cancer patients with RAS mutations.

Study Start Date: May 19

Study Type: INTERVENTIONAL

Condition: CRC, Colorectal Cancer

Intervention: DRUG: Tunlametinib combined with Fruquintinib

Tunlametinib combined wit...